Mobile

Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Hae...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004202-24

Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this trial is to evaluate the efficacy of rFVIIa (NovoSeven®/Niastase®) in reducing disability and improving clinical outcome by preventing early haematoma growth in patients with acute intracerebral haemorrhage (ICH)

Critère d'inclusion

  • Acute Intracerebral Haemorrhage

Liens